

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

 **Binding Site**
part of Takeda Oncology

 **Pfizer**

 **Bristol Myers Squibb**

 **Adaptive**
biotechnologies

Premium Sponsors

 **MENARINI**
pharma

 **Stemline**
A Menarini Group Company

 **BSK**

Standard Sponsors

 **AMGEN**

 **Takeda**

 **Johnson & Johnson**
Innovative Medicine

 **sanofi**

 **GILEAD** |  **Kite**

 **CellCentric**



UK Myeloma Society Autumn Day

Integration of Immunotherapies in Myeloma Care and Amyloid Update

Thursday 6th November 2025

Hybrid Event from the Cavendish Conference Centre, 22 Duchess Mews, London W1G 9DT

Register to attend in person or watch a live stream

Joint Chairs: Dr Charlotte Pawlyn (Institute of Cancer Research)

Professor Karthik Ramasamy (Churchill Hospital, Oxford)

09.00 *Registration, coffee & exhibition*

09.25 Welcome and introduction

09.30 UK practice/access updates

09.50 College of Myeloma UK - reflections on careers in myeloma

Professor Karthik Ramasamy
Churchill Hospital, Oxford

Dr Roger Owen
Leeds Teaching Hospitals

Professor Mark Drayson
University of Birmingham

EHA Abstract Award Winners

10.10 Challenging the concept of functional high-risk myeloma through advanced transcriptional and genetic profiling

Age-associated macrophage polarization to an M2 phenotype drives myeloma proliferation in the aged bone marrow by loss of tumor-associated phagocytosis

Dr Sina Beer
Institute of Cancer Research

Dr Dominic Fowler-Shorten
University of East Anglia

10.25 *Coffee & exhibition*

10.55 **IMS Abstract Award Winners**

The perceptions of frailty and how frailty is assessed in patients living with myeloma – a qualitative exploration of patient perspectives

Monitoring and management of CMV and other viral reactivations with bispecific antibodies (BsAbs) for patients with relapsed and refractory multiple myeloma (RRMM)

Investigating the role of the BAFF-APRIL system in promoting progression of smouldering myeloma (SMM)

Anti-adhesion properties of KTX-1001, a selective NSD2/MMSET inhibitor, enhance carfilzomib sensitivity in multiple myeloma

Jenna Tate
Leeds Teaching Hospitals

Dr Alice Feast
University College London Hospitals

Dr Amatta Mirandari
University College London

Dr Devi Nandana
University of Oxford

Michael Morley Lecture

11.30 Opportunities and challenges with immunotherapy in myeloma

12.20 *Lunch, networking & exhibition*

13.20 **AGM**

Dr Paola Neri
University of Calgary

Parallel Sessions: Clinical and Scientific

UKMRA Science Forum

In person attendance only. See next page for more information.

PORTLAND ROOM

13.40
15.10
15.45
16.30

Speakers
Coffee break
Networking and collaboration session
Summary and close

*If you wish to attend this session, please ensure that you select the appropriate package when completing your registration.
Places are limited.*

Clinical Session 1: Optimising the Safe Delivery of Immunotherapies in the NHS – Practical Implementation Updates

13.40 Prevention and management of side effects with CAR-T/bispecifics

Dr Hannah Hunter
University Hospitals Plymouth

13.55 Outpatient bispecific/CAR T delivery experience

Dr Frances Seymour
Leeds Teaching Hospitals

14.10 DGH bispecific delivery experience

Dr John Jones
University of Sussex

14.25 Safe delivery of ADCs

Dr Kevin Boyd
The Royal Marsden

14.40 Panel discussion with case studies

14.55 *Coffee break*

Clinical Session 2: AL Amyloidosis Update

15.25 Updates in overall AL amyloid management for 2025

Dr Sriram Ravichandran
National Amyloidosis Centre

15.40 Focus on – cardiac amyloidosis

Dr Charlotte Manisty
Barts Health NHS Trust

15.55 Focus on – renal amyloidosis and MGRS

Dr Jenny Pinney
University Hospitals Birmingham

16.10 Interactive discussion: Structure and function of the new Amyloid network

Professor Ashu Wechalekar
National Amyloidosis Centre

Professor Guy Pratt
University of Birmingham

16.40 *Close*

Registration:

Standard Fee (until 22 October)
£75 (£50 for Scientists, Nurses & Pharmacists)

Late Fee (from 23 October)
£125 (£85 for Scientists, Nurses & Pharmacists)

Registration now open at www.collaborativeconferences.co.uk/ukmsociety

*Online registration for this meeting is for healthcare professionals only
Please indicate if you wish to attend in person or watch the live stream while completing the registration form*

Enquiries: Please contact Alex - alex@collaborativeconferences.co.uk

The UK Myeloma Society exists to improve the care of myeloma patients through education and the promotion of trials

Premium Sponsors

 **Binding Site**
part of ThermoFisher Scientific

 **MENARINI** group
A Menarini Group Company

Johnson & Johnson
Innovative Medicine

 **Pfizer**

 **GSK**

sanofi

Standard Sponsors

 **Bristol Myers Squibb**

AMGEN

 **GILEAD** |  **Kite**

Adaptive
biotechnologies

 **Takeda**

 **CellCentric**

*All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs.
Sponsors will have the opportunity to exhibit with a company stand during the meeting.*



UKMRA Science Forum at the UK Myeloma Society Autumn Day

Thursday 6th November 2025

Cavendish Conference Centre - PORTLAND ROOM

Leading the Session:

Dr Shelly Lawson (*Sheffield*) and **Dr Sarah Gooding** (*Oxford*)

13.40	Identifying tumour specific T cell clones in smouldering myeloma	Annabel Laider <i>University College London</i>
13.55	In vivo CRISPR activation screens for developing CAR T cells with superior persistence	Jongwon Yoon <i>University College London</i>
14.10	Origins of mitotic lethality in high-CIN multiple myeloma	Alex Fowler <i>University of Oxford</i>
14.25	Prevention, not cure: Investigating MGUS and the challenges of finding a needle in the peripheral blood haystack	Dr Hannah Mackay <i>University of Birmingham</i>
14.40	How do exosomes contribute to treatment failure, with the aim of uncovering key molecular mechanisms driving drug resistance in multiple myeloma	Chloe Wylie <i>Queen's University Belfast</i>
14.55	The role of compass methyltransferase in multiple myeloma	Dr Pierangela Sabbattini <i>Imperial College London</i>
15.10	<i>Coffee break</i>	
15.45	Networking / collaboration session (speed networking)	
16.30	Summary and close	

Premium Sponsors



Standard Sponsors



All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.